Analytics, not advice. Rankings and scores describe past performance and are not recommendations.

Uncategorised

Tata India Pharma & Healthcare Fund-Direct Plan-Growth

Tata Mutual Fund · Managed by Rajat Srivastava

Ask about this fund
FundScore
Latest NAV
₹39.9437
as of 07 Aug 2026
AUM
—
Expense ratio
0.64%
as of 30 Jun 2026
Inception
14 May 2026
FundScore
76/100steady
Rank #243 of 1007 · top 24%

A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.

Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
4.74%
3M
8.20%
6M
17.97%
1Y
13.57%
3Y CAGR
20.12%
5Y CAGR
15.33%
Since incep.
13.90%
Fund details
Fund manager
Rajat Srivastava
Riskometer
Very High Risk
Type
Open Ended
Portfolio turnover
92%
Volatility (3Y)
15.3%
Rating (external)
—
Investment objective

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.

Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.

Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap34.9%
Mid cap26.9%
Small cap38.2%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 30 Jun 2026.
SUN PHARMACEUTICAL INDUSTRIES LTD
equity
8.51%
MAX HEALTHCARE INSTITUTE LTD
equity
5.68%
HEALTHCARE GLOBAL ENTERPRISES LTD
equity
5.52%
DIVI LABORATORIES LTD
equity
5.12%
ABBOTT INDIA LTD
equity
4.97%
CIPLA LTD
equity
4.77%
APOLLO HOSPITALS ENTERPRISE LTD
equity
4.61%
RAINBOW CHILDRENS MEDICARE LTD
equity
4.42%
DR REDDYS LABORATORIES LTD
equity
4.26%
GLAXOSMITHKLINE PHARMACEUTICALS LTD
equity
4.12%
MANKIND PHARMA LTD
equity
3.85%
FORTIS HEALTHCARE LTD
equity
3.35%
BAYER CROPSCIENCE LTD
equity
3.20%
LUPIN LTD
equity
2.81%
SYNGENE INTERNATIONAL LTD
equity
2.73%
ALKEM LABORATORIES LTD
equity
2.64%
SAI LIFE SCIENCES LTD
equity
2.53%
PFIZER LTD
equity
2.50%
FDC LTD
equity
2.34%
GLOBAL HEALTH LTD
equity
2.32%
PROCTER & GAMBLE HEALTH LTD
equity
1.79%
CONCORD BIOTECH LTD
equity
1.76%
DR. LAL PATH LABS LTD
equity
1.64%
NEULAND LABORATORIES LTD
equity
1.60%
AJANTA PHARMA LTD
equity
1.60%
SANOFI INDIA LTD
equity
1.53%
METROPOLIS HEALTHCARE LTD
equity
1.45%
GILLETTE INDIA LTD
equity
1.23%
TORRENT PHARMACEUTICALS LTD
equity
1.02%
SUMITOMO CHEMICAL INDIA LTD
equity
0.97%